PMHNP Scope of Practice for Weight Loss/GLP-1 in North Carolina

You’re a psychiatrist or PMHNP considering adding weight loss/GLP-1 treatment to your practice — maybe to help patients dealing with antipsychotic-induced weight gain, or because you see the demand for semaglutide and tirzepatide and wonder if there’s a revenue opportunity. The short answer: yes, you can prescribe weight-loss medications, including GLP-1 agonists, via telehealth in most states — but the devil’s in the details, and those details vary wildly by state.

This isn’t psychiatric prescribing. You’re venturing into territory with obesity medicine rules, consumer protection laws, and — if you’re prescribing controlled substances like phentermine — a minefield of DEA regulations that just got extended through 2026 but could tighten up any day. Let’s walk through what you actually need to know.

The Federal Picture: DEA Rules and the 2026 Extension

Here’s the deal with controlled substances via telehealth right now:

Under normal (pre-COVID) federal law — the Ryan Haight Act — you needed an in-person exam before prescribing any controlled substance via telemedicine. During the pandemic, that requirement was waived. As of January 2026, HHS and DEA extended those flexibilities through December 31, 2026, meaning you can still prescribe Schedule II-V controlled substances via telehealth to new patients without seeing them face-to-face first.

But this is temporary. DEA is drafting permanent rules that will likely require either a ‘special telemedicine registration’ or impose limits (like initial 30-day supplies for Schedule II stimulants). For psychiatrists prescribing Adderall or other ADHD meds, this matters. For weight loss, here’s the key distinction:

GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound) are NOT controlled substances. You can prescribe them via telehealth with zero DEA restrictions — just normal prescribing standards.

Phentermine (Adipex-P) IS a Schedule IV controlled substance. Right now, under the federal extension, you can prescribe it via telehealth. But once DEA’s new rules drop (likely 2027), you might need that in-person visit or special registration. And some states already require in-person exams regardless of federal rules.

Bottom line for federal compliance:

• Through 2026, you’re clear to prescribe controlled weight-loss meds (phentermine, etc.) via telehealth
• GLP-1s have no federal telehealth restrictions — ever
• Check your state’s rules, because states can and do override federal permissiveness

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Reality Check: Where the Rules Actually Bite

New York: The Strictest State

New York just amended its regulations in May 2025 to require an in-person medical evaluation before prescribing any controlled substance via telehealth. There are narrow exceptions — if another provider saw the patient in person within 12 months, or in emergencies for existing patients (5-day supply max) — but basically, if you’re a New York psychiatrist wanting to start a patient on phentermine via telehealth alone, you can’t.

For non-controlled meds (GLP-1s, metformin, etc.), you’re fine with telehealth. But NY’s rule means controlled substances = need that face-to-face at some point.

PMHNP consideration: New York allows experienced NPs (3,600+ hours) to practice independently, but even then, treating obesity might be questioned as outside a psych NP’s scope. If you’re doing it, document additional training or collaboration with primary care/endocrinology.

Florida: Permissive for Psychiatry, Strict for Weight Loss

Florida has a weird carve-out: you cannot prescribe Schedule II controlled substances via telehealth… unless it’s for a psychiatric disorder. So a Florida psychiatrist can prescribe Adderall for ADHD via video call (the psychiatric exception), but couldn’t prescribe amphetamines for weight loss via telehealth (not a psych disorder).

Phentermine (Schedule IV) is fine via telehealth for weight loss in Florida. But Florida has specific obesity prescribing rules:

• Patient must have BMI ≥30 (or ≥27 with comorbidities)
• You must obtain written informed consent documenting risks
• You must re-evaluate the patient every 3 months minimum
• You must provide Florida’s ‘Weight-Loss Consumer Bill of Rights’

These rules apply to all prescribers treating obesity — psychiatrist or not. If you’re a PMHNP in Florida, you’ll need a supervising physician (unless you have autonomous practice status, which most psych NPs don’t yet have in FL).

California: Watch the Corporate Practice Rules

California allows telehealth prescribing with no in-person requirement — as long as you conduct an ‘appropriate examination’ via video. For controlled substances, you must check the CURES PDMP database before the first prescription and every 4 months after.

The catch for California: corporate practice of medicine doctrine. Only physicians (or physician-owned entities) can provide medical services. If you’re launching a weight-loss telehealth service, it needs to be structured as a medical corporation owned by a physician. Non-physicians (including psych NPs) can’t independently own or control the practice.

NP autonomy note: AB 890 phases in independent practice for experienced NPs through 2026, but it’s limited to their scope. A Family NP could potentially run an independent weight-loss practice; a psych NP treating obesity would be on shakier ground without additional certification.

Texas: Flexible, But Document Everything

Texas embraces telehealth — no in-person exam required for prescribing via video, including controlled substances (under the federal extension). You can prescribe phentermine or GLP-1s remotely.

Texas requires checking the PMP (AWARxE) for controlled substances and sending a report to the patient’s primary care provider within 72 hours of a telehealth visit (if the patient consents).

NP/PA consideration: Texas NPs need a Prescriptive Authority Agreement with a physician to prescribe anything. If you’re a psych NP wanting to do weight loss, your supervising MD should ideally be someone with relevant expertise (family medicine, endocrinology), and the agreement should explicitly cover obesity treatment medications.

Pennsylvania: No Telehealth Statute, Standard of Care Rules

Pennsylvania has no comprehensive telehealth law, so you follow general medical board standards. Video exam = valid patient relationship for prescribing. For controlled substances, PA requires checking the PDMP before prescribing opioids and benzos (recommended for all controlled meds as best practice).

NP/PA: Pennsylvania CRNPs need collaborative agreements to prescribe. No independent practice yet. A psych NP in PA treating obesity should probably have a primary care physician as collaborator to cover the scope question.

Illinois: NP-Friendly, Full Practice Authority Available

Illinois is one of the more progressive states: experienced NPs can obtain Full Practice Authority (after 4,000 hours and additional training), allowing them to prescribe Schedule II-V controlled substances independently.

Telehealth is fully supported — no in-person requirement. You must check the Illinois PMP for Schedule II narcotics; other controlled substances aren’t mandatory but recommended.

Practical reality: A psych NP with FPA in Illinois could legally open a weight-loss telehealth practice, but should be prepared to justify clinical competence if ever questioned (additional training, collaboration, etc.).

Psychiatrist vs. PMHNP: Scope of Practice Reality

Psychiatrists (MD/DO):

You have unrestricted prescribing authority. Legally, you can prescribe weight-loss medications — you’re a fully licensed physician. The medical board will hold you to the standard of care for obesity treatment (which means documenting appropriate evaluations, BMI, comorbidities, informed consent, and follow-up).

Practical considerations:

• Are you comfortable managing GI side effects from GLP-1s?
• Can you counsel on nutrition and exercise, or will you coordinate with dietitians?
• Do you understand drug interactions (e.g., how phentermine might affect a patient on SSRIs or mood stabilizers)?

If you’re treating patients with serious mental illness who’ve gained 40 pounds on olanzapine, prescribing metformin or a GLP-1 makes total clinical sense. If you’re just chasing the GLP-1 revenue wave with cosmetic weight loss patients, make sure you’re truly qualified — state boards will scrutinize whether you’re practicing outside your expertise.

PMHNPs:

Your scope is mental health. Prescribing for obesity alone — not as part of treating a psychiatric condition — may be viewed as outside your scope by state nursing boards.

Ways to stay compliant:

• Obtain additional certification (e.g., Obesity Medicine certification from boards like ABOM — yes, NPs can get certified)
• Collaborate with or get protocols from a physician with relevant expertise (family medicine, endocrinology)
• Document that weight management is part of holistic psychiatric care (e.g., addressing metabolic syndrome in patients on antipsychotics)
• Practice in states with clear NP autonomy and no scope restrictions (Illinois with FPA, California under AB 890 eventually)

Reality check: Many psych NPs successfully run weight-loss services, but they structure them carefully — often with an MD medical director on paper, or by limiting practice to patients also under their mental health care.

The Economics: Why Klarity Makes Sense vs. DIY Marketing

Let’s talk money, because that’s probably why you’re reading this.

If you try to build your own weight-loss telehealth practice, here’s what you’re up against:

SEO (building a website, ranking on Google):

• Takes 6-12 months of consistent content creation, backlinks, technical optimization
• Costs: $2,000-5,000/month for an agency, or hundreds of hours of your time
• Result: maybe you start getting organic leads after a year

Google Ads (PPC):

• Mental health and weight loss keywords cost $15-40+ per click
• Most clicks don’t convert (someone Googles ‘Ozempic online,’ clicks your ad, then bounces)
• Realistic cost per booked patient: $200-400+ after ad spend, landing page optimization, failed campaigns, and no-shows

Psychology Today / Directory Listings:

• Monthly subscription fees ($30-100+)
• You’re competing with hundreds of other providers on the same page
• Zocdoc charges $35-100+ per booking, plus monthly fees
• Still need to convert those leads yourself (phone calls, intake paperwork, scheduling hassles)

Total realistic monthly cost to acquire 10-20 new patients DIY: $3,000-5,000, with no guarantee of results, plus your time managing marketing vendors and handling unqualified leads.

Here’s how Klarity Health’s model works differently:

• Pay only when a qualified patient books with you. No monthly subscriptions, no wasted ad spend testing what works.
• Pre-qualified patient flow. Patients are already matched to your specialty and availability — you’re not sorting through tire-kickers or people looking for benzos.
• Built-in telehealth infrastructure. No separate EHR, video platform, or scheduling software to buy and maintain.
• Both insurance and cash-pay options. You decide your panel mix.
• You control your schedule. Set your availability, accept or decline patients based on clinical fit.

The listing fee per new patient is transparent and predictable — compare that to gambling $4,000/month on Google Ads hoping to get 10 bookings, half of whom no-show.

For weight loss/GLP-1 specifically, patient acquisition is even harder because:

• High competition (every telehealth startup is chasing this market now)
• Expensive keywords (everyone’s bidding on ‘semaglutide prescription online’)
• Regulatory scrutiny means you need perfect compliance messaging (can’t just run Facebook ads promising ‘lose 20 pounds in a month’)

Klarity handles the patient acquisition cost and risk. You focus on clinical care. That’s the value proposition — and for providers starting out or scaling, it’s the difference between profitable patient volume and burning cash on marketing experiments.

Practical Compliance Checklist for Weight Loss Telehealth

Before you prescribe weight-loss meds via telehealth, make sure you:

1. Verify state licensure — You must be licensed in the state where the patient is located during the video visit.

2. Obtain telehealth consent — Many states (CA, IL, others) require documented patient consent for telehealth services. Have them sign something acknowledging they understand it’s remote care.

3. Conduct an appropriate examination — Document BMI, weight history, attempted diet/exercise, comorbidities (diabetes, hypertension), contraindications to medications. For GLP-1s, discuss injection technique. For phentermine, assess cardiovascular risk and psych history (anxiety, mania).

4. Check the PDMP for controlled substances — If prescribing phentermine or any controlled med, query your state’s prescription monitoring database. Document the check in your notes. Some states (CA, NY) have specific frequency requirements (every 4 months, every time, etc.).

5. Provide informed consent for medications — Many states (FL, NJ) require written informed consent for weight-loss drugs, documenting risks like GI side effects, cardiovascular effects, potential dependency for stimulants, etc.

6. Schedule appropriate follow-up — Florida requires every 3 months minimum. Virginia requires 30 days. Best practice: monthly follow-ups initially to monitor tolerance, dose titration, and side effects. GLP-1s typically need dose adjustments every 4 weeks.

7. Coordinate with primary care — Texas explicitly requires sending a report to the patient’s PCP (with consent). Even where not required, it’s good practice and reduces liability. You don’t want to be the only provider who knows a patient is on semaglutide when they show up to the ER with pancreatitis.

8. Use e-prescribing and HIPAA-compliant platforms — Many states mandate e-prescribing for all medications (NY, CA, IL). Controlled substances often require EPCS (Electronic Prescribing for Controlled Substances). Your video platform must be HIPAA-compliant (Zoom for Healthcare, Doxy.me, etc. — not consumer Zoom).

9. Document like you’re going to be audited — Because you might be. State medical boards increasingly review telehealth prescribing. Your notes should show the same level of detail as an in-person visit: chief complaint, history, exam findings (even if via video), assessment, and plan with rationale for the medication choice.

10. Stay current on regulations — DEA rules are changing. State laws evolve (NY just tightened in 2025; CA’s NP independence phases in through 2026). Subscribe to your state medical board updates, join professional groups (ASBP, ATA), or work with a compliance consultant.

FAQ: What Providers Actually Ask About Weight Loss Telehealth

Q: Can I prescribe Ozempic (semaglutide) for weight loss via telehealth to patients I’ve never seen in person?

A: Yes, in most states. Semaglutide is not a controlled substance, so there’s no DEA in-person requirement. You need to conduct an appropriate telehealth evaluation (video visit documenting BMI, medical history, etc.) that meets your state’s standard of care. States like New York, California, Texas, Florida, Pennsylvania, and Illinois all allow this — just follow each state’s telehealth rules (consent, exam standards, follow-up).

Q: What about phentermine (Adipex-P)? Can I prescribe that via telehealth?

A: Through December 31, 2026, yes — federally. The DEA extension allows telehealth prescribing of controlled substances without an in-person exam. However, check your state:

• New York: NO — requires in-person exam for controlled substances (with narrow exceptions)
• Florida, Texas, California, Pennsylvania, Illinois: YES — allowed via telehealth under current rules

After 2026, federal rules may change, and you might need an in-person visit or special DEA registration.

Q: As a PMHNP, can I legally offer weight-loss treatment, or is that outside my scope?

A: It’s state-dependent and situational. Psychiatric NPs are trained in mental health, not obesity medicine, so purely cosmetic weight loss might be questioned. Ways to stay safe:

• Treat weight as part of holistic psychiatric care (metabolic syndrome in patients on antipsychotics)
• Get additional training/certification in obesity medicine
• Collaborate with or work under protocols from a physician with relevant expertise
• Practice in states with NP independence (Illinois FPA, California AB 890) and document your competence

Bottom line: A psych NP can prescribe weight-loss meds in most states if done carefully, but you’re venturing outside traditional scope, so extra due diligence is required.

Q: Do I need a DEA registration to prescribe GLP-1 agonists?

A: No. GLP-1s (semaglutide, tirzepatide) are not controlled substances. You only need a DEA registration if you’re prescribing controlled meds like phentermine, stimulants, or any Schedule II-V drug.

Q: What’s the difference between prescribing for weight loss and prescribing psychiatric meds via telehealth?

A: Regulatory: Weight loss may trigger state-specific obesity treatment rules (like Florida’s BMI requirements, quarterly follow-ups, informed consent mandates). Psychiatric meds follow general telehealth prescribing rules (which for controlled psych meds like benzos or stimulants, some states restrict heavily — see NY).

Clinical: Weight loss prescribing requires managing metabolic and GI side effects, coordinating with nutrition/exercise programs, and monitoring things like blood pressure, blood sugar, lipids — different from psych symptom monitoring. You’re also dealing with patient expectations around cosmetic results, which can be tricky (liability-wise and ethically).

Q: Can I see patients in multiple states via telehealth for weight loss?

A: Only if you’re licensed in each state where the patient is located during the visit. Most weight-loss telehealth providers either:

• Get licensed in 5-10 high-volume states (CA, TX, FL, NY, IL, PA)
• Use Interstate Medical Licensure Compact (IMLC) to expedite multi-state licensing (29 states participate as of 2025)
• Limit practice to one or two states initially

You cannot prescribe across state lines without licensure in the patient’s state — this is a hard federal and state law.

Q: How do I avoid getting flagged by state medical boards for ‘inappropriate’ telehealth prescribing?

A: Do this:

• Conduct thorough evaluations (document history, exam, rationale)
• Use video (not just phone or questionnaire) for initial visits
• Follow up regularly (don’t prescribe and disappear for 6 months)
• Check PDMPs for controlled substances
• Coordinate with patients’ other providers
• Stay within your training and expertise (or get additional training/consultation)
• Avoid marketing that promises unrealistic results or looks like a pill mill (‘Get Ozempic in 15 minutes!’)

Don’t do this:

• Prescribe based solely on an online form with no real-time interaction
• Ignore state-specific requirements (like Florida’s obesity rules or NY’s in-person rule for controlled substances)
• Prescribe outside your scope (psych NP prescribing weight loss with no additional training and no collaboration)
• Fail to document or follow up

Medical boards review complaints and sometimes audit high-volume telehealth prescribers. If your documentation shows you’re practicing to standard, you’re fine. If it looks like you’re rubber-stamping prescriptions for cash, you’re in trouble.

The Bottom Line: Should You Add Weight Loss/GLP-1 to Your Practice?

If you’re a psychiatrist:

• You’re legally allowed to prescribe weight-loss medications (including GLP-1s and phentermine)
• It makes clinical sense if you’re treating patients with antipsychotic-induced weight gain or metabolic syndrome
• Follow your state’s obesity treatment guidelines (BMI documentation, informed consent, follow-up intervals)
• Don’t just chase revenue — make sure you’re competent to manage the medications and side effects

If you’re a PMHNP:

• You can prescribe weight-loss meds in most states, but you need to navigate scope-of-practice carefully
• Best approach: frame it as part of psychiatric care, get additional training, or collaborate with a physician
• States with NP autonomy (Illinois FPA, California AB 890) give you more room, but document your qualifications
• Avoid operating in states with unclear NP scope or strict supervision rules unless you have physician backing

The market opportunity is real:

• High patient demand (GLP-1s are cultural phenomena right now)
• Underserved populations (obesity rates >40% in many states, limited bariatric specialists)
• Good reimbursement (insurance increasingly covers GLP-1s for obesity; cash-pay patients will pay $200-400+/month)

The risks are also real:

• Regulatory scrutiny (state boards are watching telehealth weight-loss prescribing closely)
• Liability (adverse events, patient expectations, coordination failures)
• Reimbursement uncertainty (some states like California cutting Medicaid coverage for weight-loss GLP-1s in 2026)

Klarity’s platform removes the biggest barrier — patient acquisition cost and risk. Instead of spending $3,000-5,000/month gambling on marketing with uncertain ROI, you pay per patient when they book. You get pre-qualified leads, built-in telehealth infrastructure, and compliance support. For providers expanding into weight loss or scaling their psychiatric practice, that’s the difference between profitable growth and burning cash.

The regulations are navigable. The clinical care is manageable. The economics work — if you structure it right. If you’re ready to add weight loss to your practice, make sure you understand your state’s rules, practice within your competence, and prioritize patient safety. Done right, it’s a legitimate way to help patients and grow your income. Done wrong, it’s a fast track to medical board complaints and bad outcomes.

Want to explore joining Klarity’s provider network for psychiatric care or weight loss services? We handle patient acquisition, credentialing, and compliance — you handle clinical care. That’s the model. Reach out to see if it fits your practice goals.

References and Sources

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026) — https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act, 2019; accessed November 2025) — http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity (Effective August 8, 2022) — https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 30, 2024) — https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. McDermott Will & Emery – ‘Weight-Loss Programs in Florida: State Law Considerations for GLP-1 Telehealth Providers’ (September 29, 2023) — https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

6. Medical Director Compliance Consulting – ‘California Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (2025) — https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

7. Medical Director Compliance Consulting – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (2025) — https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

8. New York Codes, Rules & Regulations Title 10, §80.63 – NY DOH Regulation on Prescribing (Amended May 2025) — https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

9. New York Codes, Rules & Regulations Title 10, §80.62 – NY DOH Regulation on Use of Controlled Substances in Treatment (Amended May 2025) — https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.62

10. Fierce Healthcare – ‘Primary care doctors concerned about telehealth GLP-1 boom: survey’ by Heather Landi (February 13, 2025) — https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

11. California Medical Association – ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal’ (December 2, 2025) — https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

12. Center for Connected Health Policy – ‘State Telehealth Policies for Online Prescribing’ (Updated November 21, 2025) — https://www.cchpca.org/topic/online-prescribing/

13. Pennsylvania Department of Health – Prescription Drug Monitoring Program FAQs (2022; accessed 2025) — https://www.pa.gov/guides/prescription-drug-monitoring-program-pennsylvania/

14. U.S. Drug Enforcement Administration – ‘DEA Announces Three New Telemedicine Rules’ (January 16, 2025) — https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

15. Cornell Law School Legal Information Institute – New York State Regulations (10 NYCRR §80.62 and §80.63) — https://www.law.cornell.edu/regulations/new-york/

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated